ARA-290 is a new type of drug that is primarily used to treat diabetic retinopathy (DME). Its mechanism of action is not yet clear, but it is known that it can inhibit the expression of vascular endothelial growth factor (VEGF), thereby reducing the permeability of retinal capillaries, reducing intravascular pressure, and improving retinal function and morphology (refer to relevant literature)
